TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Trisalis Life Sciences first quarter 2026 earnings conference call. All participants are currently in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Pfeffer, Managing Director with LifeSci Advisors. Please go ahead. Thank you, Operator, and thank you all for joining us today. With me from Trisalis Life Sciences are Mary Della, President and Chief Executive Officer, David Patience, Chief Financial Officer, and Dr. Richard Marshall, Medical Director. Mary will provide an overview of our first quarter results and our strategy for the balance of the year. David will then walk through the financial results in detail. Dr. Marshall will join Mary and David for the Q&A portion of the call. Earlier today, Trisalis released its financial results for the quarter ended March 31, 2026. A copy of the press release is available on the Trisalis Investor Relations website. Today, Trisalis also announced the publication of a landmark real-world evidence study evaluating the clinical and economic impact of our pressure-enabled drug delivery, or PEDD, technology. Mary will discuss that study in detail. Before we begin, I would like to remind you that during today's call, management will make forward-looking statements within the meaning of the federal security laws. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact, including, without limitation, statements regarding our sales and operating trends, business and hiring prospects, financial and revenue expectations, and ...